Skip to main content

Table 2 Patient Characteristics

From: A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

Characteristics Safety set Immunologic set
n = 12 n = 11
Age in years, median (range) 48 (31, 62) 49 (31, 62)
  n (%) n (%)
Gender
 Female 12 (100%) 11 (100%)
Race
 Caucasian 12 (100%) 11 (100%)
Ethnicity
 Non-Hispanic 12 (100%) 11 (100%)
Menopausal Status
 Post-menopausal 8 (67%) 7 (64%)
 Pre-menopausal 4 (33%) 4 (33%)
Pathologic Type
 Ductal 11 (92%) 11 (100%)
 Unknown 1 (8%)  
Histologic Grade
 Grade II 3 (25%) 3 (27%)
 Grade III 8 (67%) 7 (64%)
 Unknown 1 (8%) 1 (9%)
Stage
 II 3 (25%) 3 (27%)
 III 9 (75%) 8 (73%)
ER Status
 Negative 5 (42%) 5 (45%)
 Positive 7 (58%) 6 (55%)
PR Status
 Negative 6 (50%) 6 (55%)
 Positive 6 (50%) 5 (45%)
Her 2/Neu Status
 Negative 6 (50%) 5 (45%)
 Positive 5 (42%) 5 (45%)
 Unknown 1 (8%) 1 (9%)
On Hormonal Therapy
 No 6 (50%) 5 (45%)
 Yes 6 (50%) 6 (55%)
 Type
  Arimidex 3 3
  Tamoxifen 3 3
HLA type (may be multiple)
 A1 7 (58%) 7 (64%)
 A2 5 (42%) 4 (36%)
 A3 6 (50%) 6 (55%)